NasdaqGS - Nasdaq Real Time Price USD
Exelixis, Inc. (EXEL)
At close: 4:00 PM EST
After hours: 4:57 PM EST
Research Analysis
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 14 | 5 | 13 | 15 |
Avg. Estimate | 0.49 | 0.39 | 1.95 | 1.96 |
Low Estimate | 0.25 | 0.28 | 1.73 | 1.37 |
High Estimate | 0.75 | 0.48 | 2.22 | 2.45 |
Year Ago EPS | 0.33 | 0.17 | 0.9 | 1.95 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 15 | 7 | 18 | 21 |
Avg. Estimate | 561.68M | 496.33M | 2.16B | 2.18B |
Low Estimate | 548M | 470.1M | 2.15B | 1.96B |
High Estimate | 579M | 515.73M | 2.18B | 2.4B |
Year Ago Sales | 479.65M | 425.23M | 1.83B | 2.16B |
Sales Growth (year/est) | 17.10% | 16.72% | 18.14% | 1.03% |
Earnings History
CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
---|---|---|---|---|
EPS Est. | 0.31 | 0.29 | 0.37 | 0.42 |
EPS Actual | 0.33 | 0.17 | 0.84 | 0.47 |
Difference | 0.02 | -0.12 | 0.47 | 0.05 |
Surprise % | 6.80% | -40.64% | 129.85% | 12.02% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.49 | 0.39 | 1.95 | 1.96 |
7 Days Ago | 0.4 | 0.36 | 1.79 | 1.77 |
30 Days Ago | 0.4 | 0.39 | 1.79 | 1.74 |
60 Days Ago | 0.4 | 0.39 | 1.8 | 1.76 |
90 Days Ago | 0.43 | 0.34 | 1.37 | 1.69 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 8 | 3 | 11 | 10 |
Up Last 30 Days | 8 | 2 | 11 | 10 |
Down Last 7 Days | 2 | -- | 1 | 2 |
Down Last 30 Days | 2 | -- | 1 | 2 |
Growth Estimates
CURRENCY IN USD | EXEL | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 47.51% | -- | -- | 5.00% |
Next Qtr. | 131.76% | -- | -- | 12.00% |
Current Year | 116.94% | -- | -- | 2.10% |
Next Year | 0.52% | -- | -- | 12.20% |
Upgrades & Downgrades
Maintains | Guggenheim: Buy to Buy | 10/30/2024 |
Maintains | Stephens & Co.: Equal-Weight to Equal-Weight | 10/30/2024 |
Maintains | Piper Sandler: Overweight to Overweight | 10/30/2024 |
Reiterates | RBC Capital: Outperform to Outperform | 10/30/2024 |
Maintains | Truist Securities: Buy to Buy | 10/30/2024 |
Maintains | Wells Fargo: Overweight to Overweight | 10/30/2024 |
Related Tickers
INCY Incyte Corporation
71.72
+1.89%
ADMA ADMA Biologics, Inc.
21.18
-0.56%
UTHR United Therapeutics Corporation
372.89
+1.51%
CPRX Catalyst Pharmaceuticals, Inc.
21.48
+1.70%
CORT Corcept Therapeutics Incorporated
57.54
+2.90%
ACAD ACADIA Pharmaceuticals Inc.
16.37
+1.17%
IONS Ionis Pharmaceuticals, Inc.
34.01
+0.21%
MDGL Madrigal Pharmaceuticals, Inc.
347.45
+5.53%
HALO Halozyme Therapeutics, Inc.
49.00
+7.22%
JAZZ Jazz Pharmaceuticals plc
126.67
+1.25%